Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: role of genetic thrombophilia
L Amitrano, V Brancaccio, MA Guardascione… - …, 2002 - thieme-connect.com
L Amitrano, V Brancaccio, MA Guardascione, M Margaglione, M Sacco, R Martino…
Endoscopy, 2002•thieme-connect.comResults: Portal vein thrombosis developed in 16% of the patients (10 of 61) after a mean
follow-up period of 16 months. A genetic cause for thrombosis was found in 70% of patients
with liver cirrhosis who developed portal vein occlusion, but only in 8% of patients without
this complication. Conclusions: Endoscopic sclerotherapy of esophageal varices may
represent a trigger factor for portal vein thrombosis in cirrhotic patients with genetic
thrombophilia.
follow-up period of 16 months. A genetic cause for thrombosis was found in 70% of patients
with liver cirrhosis who developed portal vein occlusion, but only in 8% of patients without
this complication. Conclusions: Endoscopic sclerotherapy of esophageal varices may
represent a trigger factor for portal vein thrombosis in cirrhotic patients with genetic
thrombophilia.
Results: Portal vein thrombosis developed in 16% of the patients (10 of 61) after a mean follow-up period of 16 months. A genetic cause for thrombosis was found in 70% of patients with liver cirrhosis who developed portal vein occlusion, but only in 8% of patients without this complication.
Conclusions: Endoscopic sclerotherapy of esophageal varices may represent a trigger factor for portal vein thrombosis in cirrhotic patients with genetic thrombophilia.
Thieme Connect